# LAI Intelligence Weekly P1 Test – 2025-12-12

This week highlights significant advances in long-acting injectable technologies with a major partnership and FDA approval in the schizophrenia treatment space.

## TL;DR

- Nanexa partners with Moderna to develop long-acting injectable formulations using PharmaShell® technology
- Teva's UZEDY® receives FDA approval as extended-release injectable treatment for schizophrenia

---

## Top Signals – LAI Ecosystem

Key developments this week include a strategic technology partnership and a regulatory milestone for schizophrenia treatment.

**Nanexa and Moderna Announce PharmaShell® LAI Technology Partnership**  
Nanexa AB has entered into a partnership with Moderna to develop long-acting injectable formulations utilizing Nanexa's proprietary PharmaShell® technology platform. This collaboration aims to extend the duration of therapeutic effect for Moderna's pharmaceutical products.  
[Read more](#)

**UZEDY® (aripiprazole) Extended-Release Injectable Receives FDA Approval**  
Teva Pharmaceuticals announced FDA approval of UZEDY®, an extended-release injectable formulation of aripiprazole for the treatment of schizophrenia. This approval provides patients with a new long-acting treatment option in the antipsychotic medication category.  
[Read more](#)

---

## Partnerships & Deals

Strategic collaborations are advancing the development of next-generation long-acting injectable technologies.

**Nanexa and Moderna Announce PharmaShell® LAI Technology Partnership**  
Nanexa AB has entered into a partnership with Moderna to develop long-acting injectable formulations utilizing Nanexa's proprietary PharmaShell® technology platform. This collaboration aims to extend the duration of therapeutic effect for Moderna's pharmaceutical products.  
[Read more](#)

---

*Newsletter générée par Vectora Inbox – Powered by Amazon Bedrock*
